AU2020337333A1 - IgM glycovariants - Google Patents

IgM glycovariants Download PDF

Info

Publication number
AU2020337333A1
AU2020337333A1 AU2020337333A AU2020337333A AU2020337333A1 AU 2020337333 A1 AU2020337333 A1 AU 2020337333A1 AU 2020337333 A AU2020337333 A AU 2020337333A AU 2020337333 A AU2020337333 A AU 2020337333A AU 2020337333 A1 AU2020337333 A1 AU 2020337333A1
Authority
AU
Australia
Prior art keywords
igm
seq
amino acid
chain
variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020337333A
Other languages
English (en)
Inventor
Ramesh Baliga
Bruce Keyt
Dean Ng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IGM Biosciences Inc
Original Assignee
IGM Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IGM Biosciences Inc filed Critical IGM Biosciences Inc
Publication of AU2020337333A1 publication Critical patent/AU2020337333A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2020337333A 2019-08-23 2020-08-21 IgM glycovariants Abandoned AU2020337333A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962891263P 2019-08-23 2019-08-23
US62/891,263 2019-08-23
PCT/US2020/047495 WO2021041250A1 (en) 2019-08-23 2020-08-21 Igm glycovariants

Publications (1)

Publication Number Publication Date
AU2020337333A1 true AU2020337333A1 (en) 2022-03-03

Family

ID=74684266

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020337333A Abandoned AU2020337333A1 (en) 2019-08-23 2020-08-21 IgM glycovariants

Country Status (11)

Country Link
US (1) US20220306760A1 (https=)
EP (1) EP4017533A4 (https=)
JP (1) JP2022545682A (https=)
KR (1) KR20220050166A (https=)
CN (1) CN114269380A (https=)
AU (1) AU2020337333A1 (https=)
BR (1) BR112022003282A2 (https=)
CA (1) CA3149350A1 (https=)
IL (1) IL290253A (https=)
MX (1) MX2022002239A (https=)
WO (1) WO2021041250A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3560954T3 (pl) 2014-04-03 2021-12-13 Igm Biosciences, Inc. Zmodyfikowany łańcuch J
IL308212A (en) 2015-01-20 2024-01-01 Igm Biosciences Inc Tumor necrosis factor-α receptor binding molecules and their uses
WO2016154593A1 (en) 2015-03-25 2016-09-29 Igm Biosciences, Inc. Multi-valent hepatitis b virus antigen binding molecules and uses thereof
EP3355913B1 (en) 2015-09-30 2024-10-30 IGM Biosciences, Inc. Binding molecules with modified j-chain
EP3356401B1 (en) 2015-09-30 2020-06-24 IGM Biosciences, Inc. Binding molecules with modified j-chain
MX2021014973A (es) 2019-06-07 2022-04-18 Adimab Llc Anticuerpos anti-cd3 de alta afinidad y metodos para su generacion y uso.
EP4377360A4 (en) * 2021-09-17 2025-10-15 Adimab Llc Anti-cd3 antibodies

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME00832B (me) * 2007-03-22 2012-03-20 Ucb Biopharma Sprl Vezivni proteini uključujući antitjela, derivate antitjela i fragmente antitjela, koji specifično vezuju cd154 i njihova upotreba
CA2780221A1 (en) * 2009-11-04 2011-05-12 Fabrus Llc Methods for affinity maturation-based antibody optimization
PL3560954T3 (pl) * 2014-04-03 2021-12-13 Igm Biosciences, Inc. Zmodyfikowany łańcuch J
EP3355913B1 (en) * 2015-09-30 2024-10-30 IGM Biosciences, Inc. Binding molecules with modified j-chain
WO2017106462A1 (en) * 2015-12-18 2017-06-22 Biogen Ma Inc. Bispecific antibody platform
WO2018136825A1 (en) * 2017-01-19 2018-07-26 Cedars-Sinai Medical Center Highly multiplexed and mass spectrometry based methods to measuring 72 human proteins
MA49279A (fr) * 2017-03-22 2020-02-05 Hoffmann La Roche Compositions d'anticorps optimisées pour le traitement de troubles oculaires
CA3083363A1 (en) * 2017-12-01 2019-06-06 Novartis Ag Polyomavirus neutralizing antibodies

Also Published As

Publication number Publication date
IL290253A (en) 2022-04-01
WO2021041250A1 (en) 2021-03-04
EP4017533A1 (en) 2022-06-29
JP2022545682A (ja) 2022-10-28
CA3149350A1 (en) 2021-03-04
EP4017533A4 (en) 2024-03-27
US20220306760A1 (en) 2022-09-29
MX2022002239A (es) 2022-03-22
CN114269380A (zh) 2022-04-01
KR20220050166A (ko) 2022-04-22
BR112022003282A2 (pt) 2022-05-24

Similar Documents

Publication Publication Date Title
US20230203173A1 (en) Tumor necrosis factor (tnf) superfamily receptor igm antibodies and uses thereof
US10899835B2 (en) IgM Fc and J-chain mutations that affect IgM serum half-life
US20220306760A1 (en) Igm glycovariants
JP7585305B2 (ja) 多量体の二重特異性抗ｃｄ１２３結合分子及びその使用
US20230203119A1 (en) Immunostimulatory multimeric binding molecules
US20220372142A1 (en) Multimeric antibodies with enhanced selectivity for cells with high target density
US20230212293A1 (en) Pd-1 agonist multimeric binding molecules
US20240076392A1 (en) Anti-cd123 binding molecules and uses thereof
CA3091144C (en) Igm fc and j-chain mutations that affect igm serum half-life
HK40043005A (en) Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof
HK1242348A1 (en) Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof
HK1242348B (en) Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application